HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER

This adverse event was reported 332 times

These drugs are most commonly taken by patients reporting HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER:

# Drug Count
0 RIBOCICLIB 205
1 LETROZOLE 156
2 LETROZOLE TABLETS 136
3 FULVESTRANT 132
4 PALBOCICLIB 42
5 DENOSUMAB 36
6 ZOLEDRONIC ACID 30
7 PACLITAXEL 28
8 PACLITAXEL (AIBUMIN-BOUND) 28
9 ALPELISIB 22
See all common drugs associated with HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER

HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 CAMIZESTRANT 1 0.0714
1 ALUMINUM CHLOROHYDRATE 1 0.0222
2 RIBOCICLIB 205 0.0063
3 FULVESTRANT 132 0.0039
4 SACITUZUMAB GOVITECAN 16 0.0033
5 LETROZOLE TABLETS 136 0.0028
6 LETROZOLE 156 0.0025
7 IBANDRONATE SODIUM 7 0.0022
8 GOSERELIN 16 0.0012
9 ABEMACICLIB 18 0.0009
See all drugs enriched for association with HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER

HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Estrogen Receptor Antagonist [EPC] 133 0.0033
1 Aromatase Inhibitor [EPC] 174 0.0015
2 Glinide [EPC] 2 0.0002
3 Microtubule Inhibitor [EPC] 34 0.0002
4 RANK Ligand Inhibitor [EPC] 36 0.0002
5 Androgen [EPC] 4 0.0001
6 Somatostatin Analog [EPC] 1 0.0001
7 Kinase Inhibitor [EPC] 75 0.0001
8 Nucleoside Metabolic Inhibitor [EPC] 23 0.0001
9 Interleukin-17A Antagonist [EPC] 3 0.0001
See all drug classes enriched for association with HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER